TS
ACHL

Thomas Steyer’s Achilles Therapeutics ACHL Stock Holding History

Thomas Steyer’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-450,000
Closed -$3.51M – 320
2021
Q3 		$3.51M Sell
450,000
-546,540
-55% -$3.6M 0.02% 203
2021
Q2 		$9.76M Sell
996,540
-3,460
-0.3% -$46.9K 0.04% 131
2021
Q1 		$16.6M Buy
+1,000,000
New +$16.6M 0.08% 110

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Thomas Steyer's ACHL Position: Q4 2021 in Review

Thomas Steyer sold out of Achilles Therapeutics (ACHL) in Q4 2021, closing a stake of 450,000 shares — an estimated $3.51M sold.

Thomas Steyer first reported a position in ACHL in Q1 2021 and held it in 3 quarters. The position peaked at $16.6M in Q1 2021. 30 funds tracked by Wall St. Rank hold ACHL as of Q4 2021.

  • Thomas Steyer reported no remaining Achilles Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Thomas Steyer sold 450,000 Achilles Therapeutics shares in Q4 2021, an estimated $3.51M.
  • Thomas Steyer first reported a position in Achilles Therapeutics in Q1 2021 and held it in 3 quarters.
  • Thomas Steyer's Achilles Therapeutics position peaked at $16.6M in Q1 2021.
  • 30 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q4 2021.

Based on Farallon Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.